## Maroof Alam

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/11642105/maroof-alam-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| 29          | 1,220                | 24      | <b>29</b> |
|-------------|----------------------|---------|-----------|
| papers      | citations            | h-index | g-index   |
| 29          | 1,469 ext. citations | 7.1     | 4.04      |
| ext. papers |                      | avg, IF | L-index   |

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 29 | MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. <i>Cancer Research</i> , <b>2018</b> , 78, 205-215  | 10.1 | 89        |
| 28 | Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer. <i>Signal Transduction and Targeted Therapy</i> , <b>2018</b> , 3, 13                                      | 21   | 20        |
| 27 | Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer. <i>Molecular Cancer</i> , <b>2017</b> , 16, 33                          | 42.1 | 32        |
| 26 | MUC1-C activates EZH2 expression and function in human cancer cells. <i>Scientific Reports</i> , <b>2017</b> , 7, 7481  | 4.9  | 29        |
| 25 | MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. <i>Oncolmmunology</i> , <b>2017</b> , 6, e1338998  | 7.2  | 28        |
| 24 | Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. <i>Oncotarget</i> , <b>2017</b> , 8, 69237-69249   | 3.3  | 5         |
| 23 | MUC1-C drives MYC in multiple myeloma. <i>Blood</i> , <b>2016</b> , 127, 2587-97  | 2.2  | 60        |
| 22 | Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. <i>Cancer Research</i> , <b>2016</b> , 76, 1538-48          | 10.1 | 59        |
| 21 | MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. <i>Oncotarget</i> , <b>2016</b> , 7, 38974-38987                         | 3.3  | 32        |
| 20 | Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. <i>Oncotarget</i> , <b>2016</b> , 7, 11756-69 | 3.3  | 83        |
| 19 | MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors. <i>Scientific Reports</i> , <b>2016</b> , 6, 26643         | 4.9  | 29        |
| 18 | MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway. <i>Molecular Cancer Research</i> , <b>2016</b> , 14, 1266-1276                    | 6.6  | 26        |
| 17 | Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2338-47               | 12.9 | 37        |
| 16 | MUC1-C Induces the LIN28B-½ET-7-⅓IMGA2 Axis to Regulate Self-Renewal in NSCLC. <i>Molecular Cancer Research</i> , <b>2015</b> , 13, 449-60                                      | 6.6  | 48        |
| 15 | Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. <i>Blood</i> , <b>2015</b> , 126, 354-62  | 2.2  | 25        |
| 14 | Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. <i>Oncotarget</i> , <b>2014</b> , 5, 2622-34  | 3.3  | 53        |
| 13 | MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. <i>Oncotarget</i> , <b>2014</b> , 5, 8893-905  | 3.3  | 48        |

## LIST OF PUBLICATIONS

MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. Blood, 2014, 124, 808-808 12 2.2 Development, characterization and efficacy of niosomal diallyl disulfide in treatment of disseminated murine candidiasis. Nanomedicine: Nanotechnology, Biology, and Medicine, **2013**, 9, 247-56  $^{6}$ 11 39 MUC1-C oncoprotein activates ERK-Q/EBP\( \text{ignaling} \) and induction of aldehyde dehydrogenase 10 61 5.4 1A1 in breast cancer cells. Journal of Biological Chemistry, 2013, 288, 30892-903 MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. 9 4.2 39 Prostate, 2012, 72, 1659-68 The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks 8 5.4 41 BAX function. Journal of Biological Chemistry, 2012, 287, 20866-75 MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 5.4 55 expression in human breast cancer cells. Journal of Biological Chemistry, 2012, 287, 10703-10713 Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Molecular Cancer 6 6.1 124 Therapeutics, **2011**, 10, 806-16 MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Science 8.8 66 Signaling, **2011**, 4, ra9 MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS ONE, 3.7 39 2011, 6, e28234 Efficacy of niosomal formulation of diallyl sulfide against experimental candidiasis in Swiss albino 5.6 19 mice. Nanomedicine, 2009, 4, 713-24 Potential of diallyl sulfide bearing pH-sensitive liposomes in chemoprevention against 6.2 2 33 DMBA-induced skin papilloma. Molecular Medicine, 2007, 13, 443-51 Use of a Liposomal Delivery System for Herbal-Based Therapeutics (with a Focus on Clove Oil) 357-367